Since 2008, Florida has been focusing its efforts on its new statewide recycling goal of 75%, to be achieved by 2020. This was later followed by an amendment in legislation to promote the production of renewable energy from waste. As a result of these changes, and others, the recycling rate in the state increased by 4% between 2012 and 2013, according to Waste Management World (http://dtn.fm/lw3BV).

These new efforts to increase Florida’s recycling rates found Jorge Caspary, director of the Division of Waste Management, urging organizations to increase their recycling efforts, since commercial municipal waste makes up approximately 55% of the total municipal solid waste in the state. Since the rise in recycling rate, the amount of solid waste has also increased, from just under 28 million tons to over 30 million, a large portion of this due to construction and demolition waste.

With this in mind, Florida’s Department of Environmental Protection (DEP) found that only about half of commercial solid waste in the state is being recycled. The department believes more commercial recycling would help the state reach its goal of a 75% recycling rate. Other organizations have the same vision and have joined the effort for a more sustainable Florida.

National Waste Management Holdings, Inc. (OTC: NWMH) is a solid waste management company located in Central Florida. The company provides solutions for full waste diversion, which include landfill, transfer stations, roll-off, mulch, and recycling services. More specifically, NWMH provides a construction and demolition (C&D) landfill in Hernando, Florida, servicing Citrus, Hernando, and Marion counties.

NWMH owns a 54 acre landfill facility and has an average annual disposal of approximately 110,000 cubic yards of construction debris. With new housing construction in the U.S. up significantly in recent years, and with further increase on the horizon, National Waste Management Holdings, Inc. plans to acquire complementary businesses, expand its national presence, and increase the operational efficiency of its existing business, all while supporting Florida’s goal to reach a 75% recycling rate target.

For more information, visit the company’s website at www.nationalwastemgmt.com

Let us hear your thoughts: National Waste Management Holdings, Inc. Message Board

The expansion in data usage and communications has continued to inflate beyond all predictions, with networks rapidly being pushed far beyond originally anticipated requirements. The unparalleled growth is expected to continue as developing technologies challenge existing capabilities, creating an unprecedented demand for improved network infrastructures and associated services.

Florida-based FTE Networks (OTCQX: FTNW) has grown to become a leading global provider of network infrastructure solutions, designing, building, and supporting networking infrastructures for major companies and government organizations in the U.S. and Europe. The company’s telecommunications and technology focused client base faces increased calls for expanding network capacity to satisfy the demands of their own customers for high-volume high-quality content at all levels. FTE’s must-meet goal is to provide the best in fast and reliable voice, data, and digital content delivery, all while living within critical cost limits. The only way to do this is by understanding the whole picture, offering integrated services and technologies in a flexible way that covers all aspects of telecommunication operation, including:

• Data Center Infrastructure
  • Infrastructure Design
  • Deployment
  • Testing And Commissioning
  • Rack, Stack, Power
  • Cold Aisle Containment And Efficiency Programs
  • Maintenance
  • Integration
  • MDU Design & Deploy
  • AC/DC Power Plants
• Fiber Optics
  • Row And Network Engineering
  • Large Scale Deployment
  • PMO
  • FTTX Solutions
  • Underground/Aerial
  • Deployment
  • Splicing & Testing
  • Fiber Characterization
  • Emergency Restoration
  • Maintenance
• Wireless Integration
  • Engineering
  • Deployment
  • Maintenance
  • DAS Installations
  • RF Installations
  • Site Surveys, Acquisition & Zoning
  • Audits
  • Fiber Backhaul Solutions
  • Full Suite Of Testing
  • Solutions
  • Decommissioning
• Surveillance & Security
  • Infrastructure Design
  • Deployment
  • Maintenance
  • Video Surveillance Design And Installation
  • Wi-Fi Installation
  • Storage Back-Up Solutions
  • Access Control

Through the leveraging of advanced technologies in creative ways, FTE has developed a remarkably flexible approach for addressing telecommunication challenges, providing a number of benefits to customers, as reflected in the company’s recent financial performance. FTE’s Q2 2016 financials show a 51% quarter over quarter revenue growth, along with improved margins. The company’s pipeline now totals approximately $166 million in annualized revenue, representing organic growth and a diversified customer base.

FTE Networks has just announced that SeeThruEquity, an independent equity research and corporate access firm, has initiated coverage on the company (available to members at www.SeeThruEquity.com/ftnw).

For additional information, visit the company site at www.FTENet.com, and its Investor Presentation at http://dtn.fm/Tg3oi.

Before the opening bell, Dominovas Energy Corporation (OTCQB: DNRG) announced that Michael Watkins, its chief operating officer and president of its fuel cell division, was recently dispatched to meet with a natural gas supplier in South Africa. Through this meeting, Dominovas Energy intends to secure a natural gas supply in order to facilitate the planned installation and operation of its RUBICON™ solid oxide fuel cell technology, including both the previously announced 50kW demonstration unit at the University of Johannesburg and additional commercial deployments currently in the company’s pipeline.

“My meetings were attended by key decision makers that highlighted their interest not only in expanding their distribution and sales of their product, but they also exhibited a true knowledge of and interest in the RUBICON’s ability to further expand consumer’s choices for electricity delivery,” Watkins stated in this morning’s news release. “The possible interaction between our companies would allow for an expanded market for them, as well as a profitable and sustainable market for the RUBICON™.”

The plan to secure a natural gas supply in South Africa comes after Dominovas Energy’s initial fuel solution of liquefied petroleum gas (LPG) was found to be problematic. LPG available in the region was found to be highly inconsistent in overall quality, and its transport created a number of logistical concerns that would hamper the viability of Dominovas Energy’s RUBICON™ technology moving forward. Using readily available natural gas as a fuel source, on the other hand, is expected to set a foundation for the company’s forward growth throughout Johannesburg and the surrounding region.

In addition to meeting with a natural gas supplier, Watkins visited with Dr. Tien Chien Jen, a professor with the University of Johannesburg’s Department of Mechanical Engineering, to further discuss the development of a research institute for the study of fuel cell systems at the University. Watkins also offered an update on the status of the ongoing natural gas supply discussions, which serve as a precursor to the highly-anticipated deployment of the 50kW RUBICON™ demonstration unit to the University of Johannesburg campus.

This morning’s announcement follows an update late last month that Dominovas Energy gave a successful presentation on the analysis of its Energy Solutions Survey to the University’s Central Technical Services Department. The survey, which aimed to identify the overall state of the institution’s energy usage, allowed Dominovas Energy to evaluate the ‘true’ cost of electricity and thermal generation on the campus while demonstrating the benefits that the RUBICON™ system could offer in terms of both capacity and efficiency.

For more information, visit www.DominovasEnergy.com

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

Snuggled away under Title IV of the American Recovery and Reinvestment Act of 2009, Congress’ response to the Great Recession was the Health Information Technology for Economic and Clinical Health (HITECH) Act. Among other things, the HITECH Act provided incentives for providers of medical services to adopt electronic health records (EHR) through ‘Meaningful Use’ (MU). Although primarily aimed at stimulating economic activity and creating jobs, the framers of the law hoped that the application of information technology to the provision of medical services would improve healthcare. Medical Transcription Billing, Corp. (NASDAQ: MTBC) (NASDAQ: MTBCP), through its integrated digital transcription and patient charting services, is showing how that can be done.

MTBC’s charting services are designed to help physicians generate accurate, timely patient charts and better manage their time. Providers can conveniently send in digital audio dictations, and MTBC transcribes complete patient charts directly to their EHR portal. A patient chart is a complete record of a patient’s key clinical data and medical history that includes demographics, vital signs, diagnoses, medications, treatment plans, progress notes, problems, immunization dates, allergies, radiology images, and laboratory and test results. With MTBC’s charting services, doctors, physician assistants and other medical professionals can have their audio patient progress notes transcribed and the information entered into the appropriate EHR.

The integrated charting services are a core part of MTBC’s proprietary EHR, ChartsPro, the adoption of which will not only make delivery of service more efficient, but allow practitioners to reach ‘Meaningful use’ standards. ‘Meaningful Use’, under the HITECH Act, is the use of certified EHR technology, like ChartsPro, to improve the quality and safety of healthcare. MU sets objectives that providers must meet in order to qualify for the Medicare, Medicaid, Children’s Health Insurance, and Health Insurance Marketplace programs administered by the Centers for Medicare & Medicaid Services (CMS).

MU objectives were set to roll out in three stages. The first stage had an implementation deadline of year-end 2012 and involved procedures and technology to capture data and share it. It was expected that, by that time, 80 percent of patients would have records that employed a certified EHR technology. In August 2016, a survey conducted by Medscape (http://dtn.fm/YR1ua), a free online resource for physicians and health professionals, found that 91 percent were currently using an EHR system but that, at the end of 2012, just 74 percent were.

Stage two, with an implementation deadline of year-end 2014, had two core objectives. Firstly, eligible professionals were being encouraged to text patients by using ‘secure electronic messaging to communicate with patients on relevant health information’; and, secondly, hospitals must ‘automatically track medications from order to administration using assistive technologies in conjunction with an Electronic Medication Administration Record (eMAR)’.

MTBC’s digital transcription and patient charting services are fully compliant with MU standards, and a new menu set objective in MU stage two is included. This allows progress notes to be created, edited and signed by the practitioner. Objectives and measures for Stage three include increased thresholds, advanced use of health information exchange functionality, and an overall focus on continuous quality improvement.

Curating patient data is important to the advance of medical science, but a doctor burdened by data collection is one with less time for patients. With the overload of documentation and clerical responsibilities brought on by EHR, having an integrated charting service such as that offered by MTBC is essential.

For more information, visit www.mtbc.com, and see the company’s fact sheet at http://ir.mtbc.com/events.cfm.

Keeping and cultivating satisfied customers is clearly a critical aspect of any company’s success. Building and maintaining strong customer relationships is key, requiring businesses to not only stay in touch with customers, but also to effectively deal with any customer service issues. The most successful businesses have been known to build the most impressive records of customer service, a growing emphasis in the competitive marketplace.

Building a strong relationship with customers is not just an inspiring sign on a wall, it takes serious time and dedication. According to Fox Business (http://dtn.fm/EI3Ai), the most important aspects of building better customer relationships for a business include making every customer interaction count, establishing connections, listening to customers, rewarding loyalty, and efficiently training employees. It is also important for businesses to stay up-to-date with the growing tech needs and opportunities.

Social media continues to develop and change, allowing businesses to interact more easily with consumers and to understand what they want or could use. It is an important tool for anticipating future customer needs and solving consumer issues. Businesses, especially small businesses, are looking to creative outside marketing services to better interact with their consumers. Moxian, Inc. (OTCQB: MOXC) offers exactly such services and more. MOXC is in the business of providing social marketing and promotion platforms that help businesses advertise and communicate via social media. The company’s services are designed to help merchants enhance their interaction with potential customers and/or buyers.

MOXC has its own platform called Moxian+User. The application consists of a proprietary virtual currency, social networking, redemption center, and game center. The company also offers the Moxian+Business application, helping merchants engage with customers, transforming them into members, and allowing them to communicate with customers when it counts.

These two platforms allow businesses to increase repeat sales by building a mobile presence, constantly updating consumers with new products, stories, news, and other information. In addition, the business application allows employees to market the business and address customer service issues while on the move.

For more information, visit the company’s website at www.Moxian.com

Let us hear your thoughts: Moxian, Inc. Message Board

Aerie Pharmaceuticals. Inc. (NASDAQ: AERI) is a publicly traded clinical stage pharmaceutical company focusing on the discovery of innovative treatments for glaucoma and other eye ailments. Its leading product candidates, Rhopressa™ and Roclatan™, are believed to be effective for most glaucoma patients, based on clinical trials results, and are currently in different stages of development in view of commercialization.

It is estimated that glaucoma patients make up the largest segment of the worldwide ophthalmic market, with glaucoma products and therapies exceeding $4.7 billion in global sales. According to National Eye Institute statistics, there are more than 2.7 million glaucoma patients in the United States at the moment. That number is expected to rise to 4.3 million by 2030.

Aerie Pharmaceuticals’ products are both designed to target glaucoma and lower intraocular pressure specifically. Developed in the form of eye drops administered once a day, both treatments have had very good results and tolerance rates during clinical trials, being designed as the first innovative ocular hypertension lowering mechanisms in more than 20 years.

The company completed its second phase 3 registration trial for lead product candidate Rhopressa™ in September 2015 and is now scheduled to file an NDA for the treatment in January 2017. The NDA filing was initially set for the third quarter of 2016, but it was pushed back to January because of an issue related to the third-party manufacturing site, according to a company press release (http://dtn.fm/6ng3R). Although not necessary for the filing, two more phase 3 clinical trials are being conducted for Rhopressa™ (netarsudil ophthalmic solution), this time focusing on the treatment’s safety. All trials so far indicated that the therapy has a consistent IOP lowering effect for the duration of treatment. Aerie also plans to further explore the positive attributes of Rhopressa™, as test results so far indicated a potential synergistic effect with prostaglandin analogues and possibly neuroprotective features.

Roclatan™ (netalsudil/latanoprost) is currently undergoing phase 3 registration trials, which commenced in September last year. The therapy is a fixed dose combination of Rhopressa™ and latanoprost, an approved glaucoma IOP treatment, and all clinical trials so far have indicated its superior efficacy over its components when taken independently. A second phase 3 trial began in March 20016, while a third one, aimed for European approval, is scheduled for the first half of 2016. If the current phase 3 trials are successful, Aerie intends on filing an NDA for this product in the second half of 2017. Based on the results reported so far, Roclatan™ has the potential of being the most efficient glaucoma and ocular hypertension treatment on the market up to this point.

In addition to these two primary product candidates, the company is also exploring Rhopressa’s possible long-term impact on diseases trabecular meshwork and conducting pre-clinical trials for AR-13154, a small molecule with demonstrated effects in reducing the size of lesions associated with age-related macular degeneration.

Financially, the company last week released its revenue report for the third quarter of 2016, which was described as ‘uneventful’ by an Aegis Capital Corp. analysis (http://dtn.fm/9j0Ow). Aerie ended Q3 with more than $255 million in cash and investments and slightly higher operating expenses, but still within the company’s expected range of $75-$85 million for 2016. The Aegis analysis reiterates a ‘Buy’ rating for the company, and a pricing target of $63, compared to the current $33.60 (on November 3 when the report was released). The report also underlines that the company’s financial performance has little impact on share prices, but rather clinical development success and regulatory approvals are more important.

For more information, visit the company’s website at www.aeriepharma.com

Recently disclosed developments to the OTCQX Best Market platform are likely to reduce the pain of going and being public for both domestic and foreign companies. In a note to clients, Jason Paltrowitz, Executive VP of Corporate Services at OTC Markets Group, outlined the enhancements, which include access by companies to globally recognized quantitative research coverage, a tightening of eligibility requirements, reduced compliance costs, increased transparency by making compliance status available to broker-dealers, and new promotional tools for companies to reach investors.

OTC Markets Group will work with Morningstar®, a leading provider of independent investment research, to provide OTCQX companies with quantitative equity ratings and research reports. To companies not covered by analysts, Morningstar will provide statistically derived quantitative metrics that mimic ratings by its analysts. The service will allow OTCQX companies to provide investors with an independent view of their performance, and investors will be better able to benchmark a company relative to its sector.

To supplement this effort, the “Research Marketplace”, a joint project with three global equity research firms, was launched in September. This online resource, undertaken with ACF Equity Research, Edison and Sidoti & Company, LLC, will provide OTCQX companies with independent research analyses and investment tools.

The bar to listing on the OTCQX has been raised. Penny stocks, shell companies and blank-check companies have been eliminated. The minimum bid price and market cap standards have been increased. An initial bid price of $0.25 and market cap of $10 million will be required for listing, while a minimum ongoing bid of $0.10 and $5 million valuation has to be maintained.

Corporate governance standards are following best practice. The board of an OTCQX company must include at least two independent directors, have an audit committee with a majority of independent directors and, at least 15 days prior to a mandatory AGM, circulate to shareholders an annual financial report.

It appears that the requirement for an OTCQX Advisor will be abolished, although the rubric to ‘submit an initial and annual OTCQX Advisor Letter’ still appears under Eligibility Standards on the OTC Markets Group website. In his note, Mr. Paltrowitz promised that the OTC compliance team would carry out the ‘ongoing company verification process – without the extra burden and expense of the OTCQX Advisor role and annual letter.’

The OTC Compliance Data File, now accessible to broker-dealers, provides important data points on 10,000 OTCQX and other global securities. This simplifies the process of identifying securities that are compliant under the SEC Penny Stock Rule and FINRA’s OTC Recommendation rule. Information in the Compliance Data File includes reporting status, shell status, audited financials status, number of market participants quoting, bankruptcy status and recent split data.

In October, a new transfer agent program designed to improve the transparency of share information was started. Under the program, SEC-registered stock transfer agents will be able to report their clients’ share data, including authorized and outstanding shares, to OTC Markets Group on a regular basis via a secure, electronic file transfer.

The requirement to be included in a Recognized Securities Manual in order to qualify for Blue Sky Manual Exemption has been abolished from the OTCQX Rules. In addition, OTC Markets Group is asking the federal government to allow OTCQX securities to be designated “covered securities”, which would make them exempt from separate state blue-sky law registration and exemption requirements. At present, 12 states have recognized the OTCQX as a securities manual for purposes of their “blue-sky manual exemption.”

Finally, the size and scope of the OTCQX Virtual Investor Conferences, CEO Interviews and Community Spotlight have been expanded, reaching over 30,000 investors to date. These initiatives are an alternative to the traditional company road show and allow more companies to tell their story to their investor community.

With these enhancements, OTC Markets Group may be driving the final nail in the coffin of FINRA’s OTCBB.

Before the opening bell, Singlepoint, Inc. (OTC: SING) gave prospective shareholders some additional insight into its plan to become one of the cannabis industry’s first merchant processors through its SingleSeed subsidiary. The update comes on the eve of a landmark Election Day during which five states will vote on ballot initiatives to legalize cannabis for recreational use, while four others will be voting to either expand or establish the availability of medical marijuana. If all of these measures pass, the total number of states with comprehensive medical marijuana laws would grow to 28, and, thanks in part to the massive scale of the State of California, roughly a quarter of the U.S. population would live in an area where recreational cannabis is legalized.

With the national market for medical and recreational marijuana on pace to reach $22 billion by 2020, according to Arcview Research, the issue of banking within the industry is becoming increasingly difficult to ignore. Despite legalization at the state level, marijuana is still illegal at the federal level, and, as a result, federal law prohibits banks and credit unions from taking money generated from this industry. Some financial institutions have started serving the cannabis industry in recent months, after the U.S. Treasury and Justice departments said that they won’t go after institutions that closely monitor their clients and report suspected wrongdoing, but these pioneers are still in the minority.

By and large, big banks won’t touch the marijuana industry, meaning that, for many operating in the space, operations are cash-only. In addition to being inconvenient for customers, a lack of banking options adds significant security risks for business owners. In this morning’s news release, Greg Lambrecht, chief executive officer of Singlepoint, suggested that this trend could be in for a change in the near future.

“The cannabis industry is on the cusp of unprecedented liberties, and we are optimistic that as more states vote to legalize the drug, policymakers will have to take a second look at how banks will be involved in payment processing,” he stated. “When the industry becomes bankable, we will already be in on the action as a ‘first mover’ with mobile technology to revolutionize the cannabis merchant processing business.”

Ahead of this forecast shift, Singlepoint recently awakened SingleSeed. The cannabis-focused subsidiary was originally established several years ago, making an impact on the industry by offering payment processing services to dispensaries in Colorado and Washington. Although the banks put a stop to these services years ago, Singlepoint intends to capitalize on its existing foothold in the cannabis industry as it continues to evolve across the country.

“Amid the rapid changes in the cannabis industry, we are geared up to offer innovations that will usher continued advancement while providing safe and secure ways to transact monies for business owners who operate their businesses within the boundaries of state laws and guidelines set forth for banks by federal authorities,” Lambrecht concluded. “SingleSeed will emerge as a trailblazer in providing consumers with convenient and secure purchases, while dispensaries benefit from accelerated growth and ‘bankable’ finances. We see it as a win-win-win situation.”

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

For a late-stage rare diseases focused boipharma innovator like Soligenix (OTCQB: SNGX), with up to $58 million of support for its Vaccines/BioDefense segment coming directly from NIAID contract funding (National Institute of Allergy and Infectious Diseases, a division of the NIH), recent news about the success of its BioTherapeutics segment is propitiously timed, amid the company’s move to uplist to NASDAQ. The company enthusiastically executed a 1:10 reverse split early last month (http://dtn.fm/mtiM2) in preparation for the uplisting, confident that the diligent advancement of its rare diseases pipeline over the preceding years has positioned Soligenix for commercial success, with multiple Phase 2b/3 clinical programs now ready to bear fruit.

A clear 50 percent reduction in the median duration of severe oral mucositis across the board (and a noteworthy 67 percent reduction in the most severely affected) in Phase 2 clinical testing (http://dtn.fm/A7huK) on head and neck cancer patients receiving chemoradiation firmly reinforces the potential of the company’s proprietary innate defense regulator (IDR) technology, upon which Soligenix’s SGX942 (http://dtn.fm/m8wGr) (containing dusquetide) is based. Oral mucositis (breakdown and atrophy of the mouth’s mucosal lining) is one of the common problems associated with chemotherapy (as well as radiation therapy or life-threatening bacterial infections), and it represents a significant unmet medical need for which there are no currently approved therapies. Such excellent efficacy results for the Phase 2 clinical trial of SGX942 gives the company a very strong BioTherapeutics candidate to go along with its novel SGX301 (http://dtn.fm/ZavH7) topical photodynamic therapy for cutaneous T-cell lymphoma (CTCL), and SGX203 (http://dtn.fm/NCc6y) oral formulation of BDP (beclomethasone dipropionate) corticosteroid for low-toxicity treatment of Pediatric Crohn’s Disease (gastrointestinal inflammation) – both of which have received FDA Orphan Drug and Fast Track designations.

SGX942’s dusquetide formulation is a first-in-class IDR (short, fully-synthetic peptides) and this Phase 2 clinical trial data provides substantial evidence about the broad-spectrum applicability of IDR technology in other areas, like the one where it was first discovered: infectious disease. Senior VP and CMO for Soligenix, Richard Straube, MD, seemed quite proud of the SGX942 program’s success, explaining that not only does the Phase 2 data validate the same unique biology of IDRs in humans that was observed in previous animal model studies, it also serves as a positive proof of concept for expansion of the IDR platform into other indications, such as infectious disease.

Furthermore, the Phase 2 clinical trial (multi-center, double-blind, placebo-controlled) data on SGX942 reinforces a pivotal concept about IDR technology’s novel mechanism of action and how it enables an extremely promising therapeutic approach vector for a host of diseases. Because IDRs are able to directly interact with a key protein (p62, or sequestosome-1) that helps regulate natural, selective cell degradation, and thus enhance the body’s own immunological tissue-healing and anti-infective capabilities – the technology is increasingly seen by many as a sort of molecular end-run.

Able to act downstream of innate immune receptors, yet upstream from cytokine and chemokine effectors, this implementation of IDR technology is based on modulating the body’s own reaction to injury/infection, and has been shown to also delimit the inflammation associated with tissue damage. Heading off inflammation at the pass by directly interacting at the key intracellular integration point is a bold approach, and a 16 percent higher complete response (tumor completely gone) at the one-month follow up for SGX942 is nothing to sneeze at.

With a strong worldwide IP position on dusquetide and related analogs, as well as Fast Track designation from the FDA for SGX942 and solid Phase 1 safety/tolerability results under its belt, the future looks bright for Soligenix’s newest rising BioTherapeutics star. Perhaps more importantly, this further validation of the potential of the IDR technology opens the door to a broad array of targets for Soligenix, ranging from antibiotic resistant/emerging infectious diseases, to GI tract inflammation. A recent report by BCC Research puts the global market for infectious disease pharmaceuticals and vaccines at around $103.5 billion as of last year, with a roughly 7.7 percent forward CAGR through 2021, when it is anticipated that the combined value of both types will be around $212 billion.

Having secured SME status with the EMA (European Medicines Agency) (http://dtn.fm/f9uO9) as of Oct 25, earlier projections about Soligenix by analysts such as Zack’s and Aegis Capital now appear to be unmistakably materializing. EMA logistical support will go a long ways toward taking SGX942 through Phase 3, and Soligenix is now auspiciously knocking on the global pharmaceutical market’s door.

Even without really going into the company’s revolutionary thermostabilization (heat stabilization) technology ThermoVax® (http://dtn.fm/HD49d), which could eliminate cold-chain production/refrigeration and give (Alum adjuvanted) vaccines long shelf lives at even higher than normal temperatures – the attractiveness of its Vaccines/BioDefense segment should leap out at investors. By working hand-in-hand with NIAID to proactively muster force against high priority bioterrorism and emerging disease fronts, via technology platforms and specific products that are able to address the institute’s primary concerns, Soligenix has positioned itself perfectly from a developmental standpoint.

As President & CEO, Chris Schaber explained in a CEO Clips broadcast on BTV-Business Television (http://dtn.fm/eC2Pg), Soligenix has been able to brilliantly leverage its government funding in order to better manage the very cash-intensive BioTherapeutics development which has now set the company up for long-term commercial success. Soligenix’s proprietary vaccine RiVax™ (Ricin Toxin Vaccine) (http://dtn.fm/F9bYC) has been developed through a series of competitive challenge grants and the company has even demonstrated a one year stability of RiVax at prolonged elevated temperatures (104 Fahrenheit) utilizing ThermoVax technology. Properties which made Soligenix’s ThermoVax technology an ideal choice for Hawaii Biotech, Inc. when it came to dry stabilizing the key antigen for their Ebola vaccine (http://dtn.fm/5sFkv). A distinct advantage over competing Ebola vaccines, which allows the vaccine to be deployed to and easily shipped/stored within precisely those high temperature regions where Filoviruses are endemic.

Soligenix’s OrbeShield® formulation of BDP for GI-ARS (Gastrointestinal Acute Radiation Syndrome) shares considerable technical overlap with the company’s SGX203 formulation for Pediatric Crohn’s Disease, and the same deep understanding of inflammation and tissue damage is apparent in the company’s SGX201 BioTherpaeutic, designed to prevent acute radiation enteritis (inflammatory bowel syndrome resulting from radiation therapy). This kind of inflammation mastery should really inform investors about the core IP valuation of Soligenix, and even if the company’s Vaccines/BioDefense division weren’t heavily government funded, it would still be an exciting commercial biopharma play on the basis of its highly novel BioTherapeutics offerings.

It would be wise to take a closer look at the company’s first-in-class photodynamic therapy for CTCL, as well as its dusquetide IDR SGX943 (http://dtn.fm/0hAiX), designed to combat even gram-negative bacteria such as the one which causes antibiotic-resistant and potentially fatal Melioidosis infection, in order to get a better sense of just how big the end market potential is for Soligenix’s tech envelope. Soligenix’s IP position is likely the real story behind the story, and it will be very interesting to see what enhanced exposure via the NASDAQ uplifting will do.

For more information, visit www.Solgenix.com

Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for the future.

To view this week’s program, visit www.MoneyTV.net

In the interview, Greg Lambrecht, chief executive officer of Singlepoint, gave shareholders an update on the awakening of the company’s SingleSeed subsidiary, which is focused on providing credit card processing solutions for the rapidly expanding cannabis industry. Originally announced in a news release earlier this week, the relaunch of SingleSeed is expected to strategically position Singlepoint to capitalize on rising demand and recent legislative shifts in the domestic cannabis market. Moving forward, the company intends to leverage key relationships with existing clients in this space to accelerate growth.

“Two years ago, we were placing point-of-sale terminals and allowing debit and credit cards to go through dispensaries, and the banks shut it down,” Lambrecht stated in the interview. “Now, with these new states coming on and the new administration, we feel very optimistic that they’re going to open those banks back up and we’re going to be back in the processing business for marijuana consumption.”

Undoubtedly, November will be a landmark month for the burgeoning cannabis industry in the United States. In addition to the presidential election on November 8, five new states will vote on ballot initiatives that would legalize cannabis for adult use, and three others will vote to legalize the drug for medicinal purposes. With most polls indicating that the majority, if not all, of these measures will likely pass, the current scale of the recreational marijuana market is expected to rapidly expand in the coming years. According to Arcview Research, the market for both medical and recreational marijuana is projected to grow from $7 billion this year to roughly $22 billion by 2020. Lambrecht believes that this market performance will lead to a shift in policy that makes banking more accessible for legal cannabis businesses.

“It’s not only more convenient for customers to use their debit or credit card to purchase cannabis, which is where we come in as a merchant processor, but those dispensaries that don’t have bank accounts can’t place their cash anywhere,” continued Lambrecht. “I think, with more and more states passing [cannabis legalization measures], the legislators in those states and also the new administration are going to have to look at allowing the banks to take debit and credit cards. That’s why we’re back in this game.”

Lambrecht wrapped up the interview by reminding shareholders of the company’s history in the marijuana space. With existing relationships and experience offering payment processing services to dispensaries in Colorado and Washington, Singlepoint is primed to benefit from the ‘green’ revolution that’s currently rolling across the nation.

“We get about five calls a week from dispensaries wondering if we can handle their processing, and, hopefully, in short order, we’re going to be able to say yes,” Lambrecht added.

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board